Manhattan Research Releases Digital DTC Relevance Rankings

Manhattan ResearchMore than 60% of U.S. adults turn to the Internet as a decision support tool in healthcare and disease management, and certain condition groups are more likely to use online health resources than others, according to pharmaceutical and healthcare market research company Manhattan Research. Acne, restless leg syndrome, and cancer patients are among the top ten therapeutic categories adopting eHealth activities, which can range from reading a health-related blog to joining an online patient community. The increasing use of consumer reliance on the Internet for health and pharmaceutical information is transforming digital direct-to-consumer (DTC) marketing from a "nice to have" tactic to an essential communication channel for pharma companies reaching consumer audiences.

Manhattan Research releases its Digital DTC Relevance Rankings, revealing which condition groups are most likely to use the Internet for health information out of a pool of over 100 therapeutic categories. The findings come from Cybercitizen Health™ v8.0, the company's consumer market research and advisory service. The Digital DTC Relevance chart shows that for some brands, such as those targeting acne, adult ADHD, and fibromyalgia patients, it's especially critical to take note of digital opportunities in shaping future DTC marketing strategies.

Digital DTC Relevance Rankings
Top Condition Groups Online for Health

Ranked by number of U.S. adults

1. Acne
2. Adult ADHD (Attention Deficit Hyperactivity Disorder)
3. Fibromyalgia
4. Migraine
5. Allergies
6. Irritable Bowel Syndrome
7. Anxiety Disorder/Social Phobia
8. Asthma
9. Restless Leg Syndrome
10. Cancer

Among U.S. adults (18+)
Source: Cybercitizen Health™ v8.0 (2008)

"This is the year in which pharmaceutical companies must stop merely 'talking at' consumers and begin communicating with them. The old way of DTC marketing isn’t going to cut it as the consumer media landscape evolves," said Meredith Abreu Ressi, Vice President of Research at Manhattan Research. "Though we've shared just a few of the top condition groups online for health, the reality is that all pharmaceutical marketers are finding that their target audiences are shifting from traditional offline sources to the Internet for their everyday needs, including health management."

Manhattan Research at the DTC National Conference
Manhattan Research Vice President of Research Meredith Abreu Ressi will be presenting "How New Media Changes Pharmaceutical DTC Advertising" with Jeff Hitchcock, President and Founder of Children with Diabetes, a Johnson and Johnson Company, at the DTC National Conference on Thursday, April 16, 2009 in Washington D.C.

For more information about the DTC National Conference, please visit: http://www.dtcperspectives.com/website/Conferences/DTC-National/DTC-National-Main.html

Request a Complimentary Overview of Digital Trends for Your Therapeutic Audience
Manhattan Research offers complimentary overviews of how over 100 consumer therapeutic groups use the Internet and other technology for healthcare. This one-page snapshot is a preview of Manhattan Research's Therapeutic Segmentation Modules, which are comprehensive analyses of specific patient markets based on the Cybercitizen Health™ and ePharma Consumer® studies. To request an overview of digital trends for your therapeutic audience, please visit http://www.manhattanresearch.com/products/Therapeutic_Segmentations/therapeutic-segmentation-overview-request.aspx

For a list of available consumer therapeutic segmentation modules and topics, please visit http://www.manhattanresearch.com/products/Therapeutic_Segmentations

For a list of available physician specialist segmentation modules and topics, please visit http://www.manhattanresearch.com/products/Specialist_Segmentations

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers, including Taking the Pulse®, Taking the Pulse® Europe, Taking the Pulse® Asia, Cybercitizen Health™, Cybercitizen Health™ Europe, ePharma Consumer®, and ePharma Physician®. Broad consumer and physician research is complemented by targeted analysis among more than 100 consumer therapeutic egments and 25 physician specialist segments. For information, please visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.decisionresourcesinc.com.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...